| |
|
|
|
The Center for Professional Advancement, An Online Training Format
May 1, 2008
Who Should Attend
This course incorporates multiphase views of conventional, biologic and generic drug sectors. Each of these sectors will impact the others significantly over the next decade - and all have drastic importance to capital markets, stockholders, legislators and the patient. Understanding these trends is vital for anyone that plans to conduct pharma business over the next fifteen years. It is recommended for:- Pharmaceutical business planners
- Drug pipeline candidate evaluators
- Quality Risk Managers
- Pharmaceutical sales, distribution and marketing personnel
- Human resources–both employers and the employed
- Investors, stockholders and business valuers
Description
This highly focused 11/2 hour course provides a top-level overview of drug-product R&D strategies, merger alternatives, legislative and consumer impact, timelines and cycles that will affect capital costs and revenue streams, change in drug portfolios and the concomitant changes in patient acceptance. The course points out strategic pathways for managing in an evolutionary operating model.
Module 1:
Market expectations vs. performance from 1980-2000The why and how of product pipeline erosionBenchmarks for evaluating plant costs vs. yieldThe rise and solidification of genericsBiologics: high risk, high reward, expensive capitalizationLegislative, regulatory and healthcare management impacts
Module 2:
Product portfolio evolution through 2020Infrastructure barriers to both change and entryThe “critical path” avenue to patient toleranceExogenous factors: counterfeiting, product identificationMarket sustainability as an aspect of patent life and the onset of competitionPathways to individual company growth
|
|
|
|
|
|
|
|
Organized by:
|
|
The Center for Professional Advancement |
|
|
Invited Speakers:
|
|
John E. Carroll, C.Ph.C. Managing Partner, Cadrai Technology Group and President, Carroll Ventures, Inc.
John E. Carroll, C.Ph.C. is Managing Partner, Cadrai Technology Group and President, Carroll Ventures, Inc. The Cadrai Technology Group develops and presents focused training programs for issues germane to the current needs of the analytical instrument industry, especially regarding Pharmaceutical applications. As Managing Partner for Cadrai LLC., Mr. Carroll modified and introduced ion mobility spectrometers for cleaning verification, an automated fiber optic/UV sensed dissolution apparatus for rapid pharmaceutical product screening and numerous Near-Infrared spectrometric systems for dedicated pharmaceutical applications. All products used proprietary technology of the principal clients.
As Pharmaceutical Business Unit Manager, for Perstorp Analytical Instruments (now Foss), Mr. Carroll built a global, sustainable business that saw over 8,000 NIR test instruments placed within the pharmaceutical manufacturing industry.
Mr. Carroll has a B.A.S in Engineering Technology/Chemistry, a M.B.A. (c) in International Marketing, fifty publications and is the author of “The NIR Desk Reference”, (Carroll, He and Landa) and “The Handbook of FTIR”, (Carroll). He is also the editor of “IR-MS: High sensitivity and selectivity for organic analysis”. (Mattson and Carroll).
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
n/a
|
|
|
|
|
|
|
|
Registration:
|
|
Please click here for registration information.
|
|
|
E-mail:
|
|
info@cfpa.com
|
|
|
|
|
|
|
|
|